Overview of the H1N1 vaccines market 

According to the analysts at Technavio, the global H1N1 vaccines market is envisaged to show stable growth and will post a CAGR of more than 4% over the forecast period. In 2006, the WHO in collaboration with vaccines manufacturers, academic experts, public health organization, and funding agencies developed a global action plan for influenza vaccines. This program was implemented with a vision to combat the global shortage of seasonal epidemic influenza vaccines and pandemic influenza vaccines. It is a comprehensive strategy to increase the production capacity and the use of seasonal and influenza vaccines. Moreover, WHO is strengthening global surveillance systems to analyze the circulating strains of influenza virus and determine the global burden of disease. Therefore, the implementation of a comprehensive action plan for influenza vaccines is one of the primary factors anticipated to bolster this market’s growth until the end of 2020.

The emergence of a universal influenza vaccine is a significant trend spurring the growth prospects of this market in the coming years. Currently, influenza vaccines are reformulated annually to offer protection against influenza viral strains that are likely to prevail in the upcoming flu season. However, these vaccines exhibit low efficacy against pandemic viruses and viruses with an antigenic mismatch. The limited effectiveness of such vaccines led to the development of a universal influenza vaccine, which is based on the protein structure of the influenza virus and are conserved across virus subtypes. This is expected to increase the window for protection against the flu virus. Also, this universal flu shot can decrease the severity of the disease and increases viral clearance from the body. Moreover, it is expected to reduce the mortality rate of influenza infection significantly till specific vaccines directed against the causative viral strain are developed.

Segmentation by route of administration and analysis of the H1N1 vaccines market

• Intramuscular vaccines
• Intranasal vaccines
• Intradermal vaccines

During 2015, the intramuscular segment dominated the market and accounted for nearly 75% of the market share. Intramuscularly administered H1N1 vaccines include Afluria, Fluarix, Flucelvax, FluLaval, Fluvirin, and Fluzone, among others and are used for treatment in people aged six months or older.

Geographical segmentation and analysis of the H1N1 vaccines market

• Americas
• APAC
• EMEA

In terms of geography, the Americas led the global H1N1 vaccines market and is expected to reach close to USD 2 billion by 2020. Factors such as the higher incidences of H1N1 infections in the US and the affordability of treatment due to well-structured reimbursement health plans to propel this market’s growth in the region. Furthermore, the increasing use of combination vaccines and the introduction of novel vaccines is anticipated to drive the growth of this market in the Americas.

Competitive landscape and key vendors

The global H1N1 vaccines market is highly competitive owing to the presence of numerous small and large suppliers. New players are looking to enter the market as the market has tremendous growth opportunities. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.

 Key vendors in this market are -

• Sanofi
• GSK
• AstraZeneca
• CSL

Other prominent vendors analyzed in this report are Abbott, Baxter International, CEL-SCI, Cipla, Crucell NV, Denka Seiken, Green Cross Corp, Hualan Biological Engineering, iBio, Imunoloski Zavod, Inovio Biomedical, Lupin, Medicago USA, Merck, Mitsubishi Tanabe Pharma, Omninvest, Panacea, Pfizer, Protein Sciences Corporation, Serum Institute of India, Sinovac Biotech, Solvay, Zhejiang Tianyuan Biopharmaceuticals, and Zydus Cadila.

Key questions answered in the report include

• What will the H1N1 vaccines market size and the growth rate be in 2020?
• What are the key factors driving the global H1N1 vaccines market?
• What are the key H1N1 vaccines market trends impacting the growth of the market?
• What are the challenges to market growth?
• Who are the key vendors in global H1N1 vaccines market?
• What are the market opportunities and threats faced by the vendors in the global H1N1 vaccines market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA. 
• What are the key outcomes of the five forces analysis of global H1N1 vaccines market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Human Vaccine Market 2016-2020
• Global Antibody Drug Conjugates Market 2016-2020
• Global Immunotherapy Drugs Market 2016-2020
• Global Travel Vaccines Market 2015-2019